Clinical trials: CNS Germ Cell Tumor
Recurrent Glioblastoma
Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
The purpose of this research is to find hidden cancer with an experimental magnetic resonance imaging (MRI) scan called spectroscopic magnetic resonance imaging (sMRI).
- Trial name
- NCT05284643
- Testing
- Intensity Modulated Proton Therapy (IMPT), Bevacizumab
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- University of Miami
Retinoblastoma, Clear Cell Sarcoma
Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors
This is a Phase I trial with new experimental drugs such as simvastatin in combination with topotecan and cyclophosphamide in the hopes of finding a drug that may work against tumors that have come back or that have not responded…
- Conditions
- Retinoblastoma, Clear Cell Sarcoma, Renal Cell Carcinoma, Rhabdoid Tumor
- Trial name
- AflacST1402 (NCT02390843)
- Testing
- Simvastatin, Cyclophosphamide, Topotecan
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Emory University
Brain and Central Nervous System Tumors
Biological Therapy and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Biological therapies such as poly-ICLC use different ways to stimulate the immune system and stop tumor cells from growing. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- Poly-ICLC (NCT00052715)
- Testing
- poly ICLC
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Diffuse Intrinsic Pontine Glioma (DIPG)
Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).
The goal of this pilot study is to determine if intra-arterial (IA) chemotherapy is safe in the treatment of progressive diffuse intrinsic pontine gliomas (DIPG).
- Trial name
- NCT01688401
- Testing
- Melphalan hydrochloride
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Brain and Central Nervous System Tumors
MRI in Evaluating the Effect of Efaproxiral on the Brain in Patients With Recurrent or Progressive Glioma Enrolled on Clinical Trial NABTT-9806
RATIONALE: Diagnostic procedures, such as MRI, may help doctors learn how efaproxiral works in the brain and help plan the best treatment.
- Trial name
- NCT00433472
- Testing
- magnetic resonance imaging (MRI)
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma, Gliosarcoma
Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
This phase I trial studies the safety and best dose of anti-LAG-3 (anti-LAG-3 monoclonal antibody BMS-986016) or urelumab alone and in combination with nivolumab in treating patients with glioblastoma that has returned…
- Conditions
- Glioblastoma, Gliosarcoma, Recurrent Brain Neoplasm
- Trial name
- NCT02658981
- Testing
- Anti-LAG-3 Monoclonal Antibody BMS 986016, Anti-PD-1, Pharmacological Study
- Where
- 11 sites in United States
- Volunteers
- 63 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Brain and Central Nervous System Tumors
Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00014105
- Testing
- carboplatin, temozolomide
- Where
- United States
- Sponsor
- Atlantic Health System
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
This phase I trial studies the side effects and determines the best dose of genetically modified neural stem cells and flucytosine when given together with leucovorin for treating patients with recurrent high-grade gliomas.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT02015819
- Testing
- E. coli CD-expressing genetically modified neural stem cells, flucytosine, leucovorin calcium
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- City of Hope Medical Center
Recurrent Diffuse Pontine Gliomas
Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma
This is a phase 2, single-arm, multi-center study, with a safety review component, designed to evaluate the efficacy and safety of nimotuzumab in approximately 44 patients with recurrent diffuse intrinsic pontine glioma (DIPG)…
- Trial name
- NCT00600054
- Testing
- nimotuzumab (anti EGFR humanized monoclonal antibody)
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 44 people
- Sponsor
- YM BioSciences
Glioblastoma Multiforme, Anaplastic Astrocytoma
INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
This is a multicenter phase 1 trial of INCB7839 for children with recurrent or progressive high-grade gliomas, including, but not limited to, diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs), after…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, DIPG
- Trial name
- NCT04295759
- Testing
- INCB7839
- Where
- 11 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pediatric Brain Tumor Consortium
Brain Tumor, Recurrent, Glioblastoma
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
The purpose of this study is to test the effectiveness of a drug called temsirolimus in combination with a drug called perifosine in treating brain tumors that have continued to grow after previous treatment.
- Conditions
- Brain Tumor, Recurrent, Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT02238496
- Testing
- Cytoreductive surgery, Perifosine, Temsirolimus
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Andrew B Lassman, MD
Glioblastoma
Efficacy of Distant Healing in Glioblastoma Treatment
This study will assess whether distant healing effects survival time and loss of function for glioblastoma patients.
- Trial name
- NCT00029783
- Testing
- Distant Healing
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Recurrent Glioblastoma Multiforme
Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)
The study is a randomized, controlled trial, designed to test the efficacy and safety of a new medical device, the NovoTTF-100A.
- Trial name
- NCT00379470
- Testing
- NovoTTF-100A
- Where
- 25 sites in United States, Austria and 5 more
- Volunteers
- 236 people
- Sponsor
- NovoCure Ltd.
Brain and Central Nervous System Tumors
Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas
RATIONALE: Lonafarnib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00083096
- Testing
- lonafarnib, temozolomide
- Where
- 3 sites in France, Switzerland
- Volunteers
- 30 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Malignant Glioma
Radionecrosis and FDG PET
Gliomas are the most common malignant primary central nervous system (CNS) tumours. When high-grade gliomas (HGG) recur, subsequent magnetic resonance (MRI) imaging, with additional sequences is required.The Positron Emission…
- Trial name
- DTPI FDG-PET (NCT02391246)
- Testing
- Positron Emission Tomography Imaging
- Where
- Canada
- Volunteers
- 62 people
- Sponsor
- Ottawa Hospital Research Institute
Brain and Central Nervous System Tumors
Tumor Tissue, Blood Samples, and Family History in Predicting Tumor Development and Response to Treatment in Young Patients With Low-Grade Glioma
RATIONALE: Studying samples of tumor tissue and blood in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00891722
- Testing
- biologic sample preservation procedure, laboratory biomarker analysis, questionnaire administration
- Where
- United Kingdom
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Children's Cancer and Leukaemia Group
Cancer, Pediatric Cancer
Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors
The primary purpose of this study is to determine the pediatric maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D), and to evaluate the safety and tolerability of zanzalintinib.
- Trial name
- NCT07773454
- Testing
- Zanzalintinib
- Volunteers
- 18 people
- Sponsor
- Exelixis
Glioma, Brain Tumor
GW572016 to Treat Recurrent Malignant Brain Tumors
This study will examine whether an experimental drug called GW572016 can delay tumor growth in patients with glioblastoma multiforme (GMB, a malignant brain tumor).
- Conditions
- Glioma, Brain Tumor, Glioblastoma Multiforme, GBM
- Trial name
- NCT00107003
- Testing
- lapatinib ditosylate, Adjuvant therapy, Conventional surgery
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
CC-5013 in Treating Patients With Recurrent Glioma
RATIONALE: CC-5013 may stop the growth of gliomas by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of CC-5013 in treating patients who have recurrent glioma.
- Trial name
- NCT00036894
- Testing
- lenalidomide
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Brain Edema, Brain Tumor
XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors
The purpose of this study is to compare the safety and efficacy of XERECEPT® to dexamethasone (Decadron) a common treatment for symptoms of brain swelling (edema).
- Trial name
- NCT00088166
- Testing
- hCRF
- Where
- 34 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Celtic Pharma Development Services
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.